As we found that the Jurkat reporter line is a good initial tool for evaluating different variants of the CD19 targeting FiCAR, we extended our studies to find active CARs against solid tumor targets such as breast cancer and neuroblastoma. Here, CD19 is linked to breast carcinoma.